Literature DB >> 28347230

Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4.

Reza Nedaeinia1,2, Mohammadreza Sharifi3, Amir Avan4, Mohammad Kazemi3, Abdolreza Nabinejad5, Gordon A Ferns6, Majid Ghayour-Mobarhan4,7, Rasoul Salehi3,8,9.   

Abstract

Colorectal cancer is among the most lethal of malignancies, due to its propensity to metastatic spread and multifactorial-chemoresistance. The latter property supports the need to identify novel therapeutic approaches for the treatment of colorectal cancer. MicroRNAs are endogenous non-coding small RNA molecules that function as post-transcriptional regulators of gene expression. Recently, programmed cell death 4 has been identified as a protein that increases during apoptosis. This gene is among the potential targets of miR-21 (OncomiR). Locked nucleic acid-modified oligonucleotides have recently emerged as a potential therapeutic option for targeting microRNAs. The aim of this study was to explore the functional role of locked nucleic acid-anti-miR-21 in the LS174T cell line in vitro and in vivo models. LS174T cells were treated with locked nucleic acid-anti-miR-21 for 24, 48, and 72 h in vitro. The expression of miR-21 and PDCD4 at messenger RNA (mRNA) level was evaluated by quantitative real-time polymerase chain reaction, while the protein level of PDCD4 was determined by Western blotting. Cell migratory behavior and the cluster-forming ability of cells were assessed before and after therapy. The disseminated tumor cells were assessed in the chick chorioallantoic membrane model by Alu quantitative polymerase chain reaction. Locked nucleic acid-anti-miR-21 was transfected successfully into the LS174T cells and inhibited the expression of miR-21. Locked nucleic acid-anti-miR-21 inhibited the migration and the number of cells forming clusters. Moreover, we found that locked nucleic acid-anti-miR-21 transfection was associated with a significant reduction in metastatic properties as assessed by the in ovo model. Our findings demonstrated the novel therapeutic potential of locked nucleic acid-anti-miR-21 in colon adenocarcinoma with high miR-21 expression.

Entities:  

Keywords:  PDCD4; colorectal cancer; locked nucleic acid-anti-microRNA; microRNA-21

Mesh:

Substances:

Year:  2017        PMID: 28347230     DOI: 10.1177/1010428317692261

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

1.  Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies.

Authors:  Shaghayegh Haghjooy Javanmard; Golnaz Vaseghi; Ahmad Ghasemi; Laleh Rafiee; Gordon A Ferns; Hajar Naji Esfahani; Reza Nedaeinia
Journal:  Cancer Cell Int       Date:  2020-08-10       Impact factor: 5.722

2.  Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.

Authors:  Urszula Dougherty; Reba Mustafi; Hongyan Zhu; Xiaorong Zhu; Dilip Deb; Stephen C Meredith; Fatma Ayaloglu-Butun; Michelle Fletcher; Arantxa Sanchez; Joel Pekow; Zifeng Deng; Nader Amini; Vani J Konda; Vijaya L Rao; Atsushi Sakuraba; Akushika Kwesi; Sonia S Kupfer; Alessandro Fichera; Loren Joseph; John Hart; Fang He; Tong-Chuan He; Diana West-Szymanski; Yan Chun Li; Marc Bissonnette
Journal:  Epigenetics       Date:  2020-12-28       Impact factor: 4.528

Review 3.  Biodistribution studies for cell therapy products: Current status and issues.

Authors:  Yoshiteru Kamiyama; Yoichi Naritomi; Yuu Moriya; Syunsuke Yamamoto; Tsukasa Kitahashi; Toshihiko Maekawa; Masahiro Yahata; Takeshi Hanada; Asako Uchiyama; Akari Noumaru; Yoshiyuki Koga; Tomoaki Higuchi; Masahiko Ito; Hiroyuki Komatsu; Sosuke Miyoshi; Sadaaki Kimura; Nobuhiro Umeda; Eriko Fujita; Naoko Tanaka; Taku Sugita; Satoru Takayama; Akihiko Kurogi; Satoshi Yasuda; Yoji Sato
Journal:  Regen Ther       Date:  2021-07-12       Impact factor: 3.419

Review 4.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

Review 5.  Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.

Authors:  Dinh-Duc Nguyen; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

Review 6.  Fusobacterium nucleatum and colorectal cancer: A review.

Authors:  Fu-Mei Shang; Hong-Li Liu
Journal:  World J Gastrointest Oncol       Date:  2018-03-15

Review 7.  microRNA biomarkers in colorectal cancer liver metastasis.

Authors:  Shulin Huang; Xiaohui Tan; Zhongcheng Huang; Zihua Chen; Paul Lin; Sidney W Fu
Journal:  J Cancer       Date:  2018-10-06       Impact factor: 4.207

Review 8.  Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions.

Authors:  Sachiko Matsuhashi; M Manirujjaman; Hiroshi Hamajima; Iwata Ozaki
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

Review 9.  Fusobacterium nucleatum-positive colorectal cancer.

Authors:  Zhenhua Yang; Guang Ji
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

10.  A novel multi-parametric analysis of non-invasive methods to assess animal distress during chronic pancreatitis.

Authors:  Ahmed Abdelrahman; Simone Kumstel; Xianbin Zhang; Marie Liebig; Edgar Heinz Uwe Wendt; Johanna Eichberg; Rupert Palme; Thomas Thum; Brigitte Vollmar; Dietmar Zechner
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.